Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors

BACKGROUND: Numerous biomarkers are being tested to enhance the ability of clinicians to predict responses and prognosis after treatment with immune checkpoint inhibitors (ICIs). Polycomb repressive complex 2 (PRC2) is a histone methyltransferase family that plays a major role in chromatin silencing...

Descripción completa

Detalles Bibliográficos
Autor principal: Vlachostergios, P.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216430/
https://www.ncbi.nlm.nih.gov/pubmed/35757234
http://dx.doi.org/10.1016/j.iotech.2021.100035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216430/
https://www.ncbi.nlm.nih.gov/pubmed/35757234
http://dx.doi.org/10.1016/j.iotech.2021.100035

Ejemplares similares